+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Human Rabies Vaccines Market by Vaccine Type, Vaccine Class, Route of Administration, Formulation, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674553
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Human Rabies Vaccines Market grew from USD 1.05 billion in 2024 to USD 1.10 billion in 2025. It is expected to continue growing at a CAGR of 4.64%, reaching USD 1.38 billion by 2030.

Navigating the Evolving Terrain of Human Rabies Vaccines

Rabies continues to pose a persistent threat across both urban and rural communities, claiming thousands of lives annually despite the availability of effective vaccines. As the only vaccine-preventable viral disease with near‐100% fatality once clinical symptoms appear, rabies underscores the critical importance of early prophylaxis programs and sustained investment in vaccine development. In recent years, the global health community has intensified efforts to eliminate human deaths from dog-mediated rabies through integrated surveillance, mass canine vaccination, and enhanced access to post-exposure prophylaxis.

Our executive summary synthesizes the most pertinent insights shaping the human rabies vaccine landscape. It highlights breakthroughs in manufacturing technologies, evolving regulatory frameworks, and the strategic impact of emerging trade policies. By mapping segmentation dynamics-from vaccine type and class to administration route, formulation, end user, and distribution channel-this overview equips stakeholders with a nuanced understanding of where growth and innovation converge. Additionally, regional perspectives and competitive intelligence illuminate the varying demands and regulatory environments across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

In sum, this introduction sets the stage for a deep dive into the transformative shifts, market drivers, and actionable opportunities that define the future of human rabies prophylaxis. Decision-makers can leverage these findings to optimize product portfolios, streamline supply chains, and accelerate public health impact worldwide.

Revolutionary Momentum Reshaping Vaccine Development

The human rabies vaccine market is undergoing a profound transformation driven by novel scientific advances and shifting public health priorities. Intradermal regimens now offer dose-sparing benefits that significantly reduce per-patient costs and broaden access in resource-limited settings. Meanwhile, innovations in cell culture platforms-including human diploid cell lines, purified chick embryo cell processes, and purified Vero cell systems-are enhancing yield consistency and reducing production timelines, permitting manufacturers to respond more agilely to outbreak scenarios.

Concurrently, stakeholders are exploring the potential of intramuscular single-dose formulations that could simplify immunization schedules and improve adherence in at-risk populations. Lyophilized thermostable presentations are also gaining traction, mitigating cold-chain constraints in remote regions and enabling decentralized immunization campaigns. At the policy level, growing alignment with One Health initiatives has mobilized cross-sector collaboration to integrate veterinary and human vaccine strategies, thereby amplifying the impact of mass immunization drives.

These technological and regulatory shifts are further catalyzed by digital health platforms that optimize post-exposure tracking and adherence monitoring, ensuring timely administration of critical booster doses. Collectively, these developments redefine the competitive landscape, offering early movers the opportunity to establish leadership in both emerging and established markets.

Tariff Dynamics Altering the US Vaccine Supply Chain

United States trade policy adjustments slated for 2025 will introduce new layers of complexity into global vaccine supply chains, with significant implications for cost structures and procurement strategies. The imposition of additional tariffs on imported biopharmaceutical intermediates and raw materials underscores the need for manufacturers to reevaluate sourcing strategies. In anticipation, several producers have begun to diversify their supplier base, forging partnerships with regional facilities in Asia-Pacific and EMEA to mitigate exposure to U.S. duties and safeguard continuity of supply.

These tariff measures elevate the cost of active ingredients, ancillary reagents, and specialized adjuvants, increasing production expenses that could be passed along to end users if manufacturers do not absorb a portion of the burden. The net effect may be a reorientation of contract negotiations, with bulk purchase agreements and long-term sourcing contracts becoming critical levers for cost containment. Moreover, domestic production capacities in North America and Europe are receiving renewed focus, as governments prioritize local manufacturing capabilities to reduce dependence on cross-border shipments.

In light of these dynamics, stakeholders must adopt a more proactive approach to supply chain resilience. Strategic stockpiling, enhanced demand forecasting, and tighter integration between operations, finance, and procurement functions will be essential to offset the cumulative impact of tariff pressures.

Deep Dive into Market Segmentation Drivers

A nuanced appreciation of market segmentation reveals the intricacies driving demand and adoption across diverse stakeholder groups. When examining vaccine type, demand for post‐exposure prophylaxis remains the dominant driver, propelled by the critical need for rapid intervention in rabies exposure cases, while pre‐exposure prophylaxis is gaining momentum among high-risk cohorts such as veterinary professionals and travelers to endemic regions. Within vaccine class, human diploid cell vaccines continue to set the standard for safety and immunogenicity, yet purified chick embryo cell and purified Vero cell options are making inroads by delivering cost‐effective scalability and reduced production lead times.

Route of administration serves as another pivotal consideration. Intradermal delivery’s dose efficacy has spurred health authorities to endorse it as a resource-saving alternative to traditional intramuscular injections, though intramuscular administration persists as the established norm in many institutions. Differences in formulation further differentiate offerings, with liquid presentations facilitating ease of use in urban hospital settings contrasted by lyophilized powders preferred in remote clinics due to their superior thermal stability and extended shelf life. End users, including private clinics, large hospital networks, and research institutes, display distinct procurement behaviors; clinics often prioritize upfront affordability, hospitals emphasize throughput and cold-chain reliability, and research institutes look for access to novel or investigational vaccines.

Finally, distribution channels underscore the evolving routes to market. Hospital pharmacies continue to hold significant sway given their integrated procurement processes, while online pharmacies enable direct-to-patient delivery models and expand reach into underserved areas. Retail pharmacies, bridging both prescription fulfillment and over-the-counter offerings in some territories, are increasingly seen as strategic partners for public health campaigns. Together, these segmentation insights equip decision-makers with a clear view of where to focus resources and tailor strategies for maximum market penetration.

Regional Market Dynamics Driving Vaccine Uptake

Regional dynamics play a decisive role in shaping vaccine adoption patterns and informing strategic investment decisions. In the Americas, robust reimbursement frameworks and established logistics infrastructure underpin steady demand for both post-exposure and pre-exposure prophylaxis. High awareness levels among health practitioners and strong government-sponsored vaccination initiatives in North America contrast with emerging federal partnerships in Latin America that aim to close coverage gaps in rural and peri-urban communities.

Europe, Middle East & Africa presents a heterogeneous landscape, where stringent regulatory requirements in European Union member states ensure high quality and safety standards, but also prolong time-to-market. Meanwhile, the Middle East is experiencing incremental growth via public-private collaborations targeting refugee and migrant populations, and select African nations are leveraging donor-supported programs to scale mass dog vaccination alongside human prophylaxis efforts. Complex geopolitical considerations and variable cold-chain capacities necessitate tailored approaches to distribution and stakeholder engagement across this region.

Asia-Pacific remains the fastest-expanding arena, buoyed by large at-risk populations, progressive policy frameworks, and growing local manufacturing capabilities. National immunization programs in South and Southeast Asia are increasingly incorporating intradermal regimens to stretch limited budgets, while East Asia sees strategic investments in advanced cell culture facilities. This region’s blend of high disease burden and dynamic industrial growth makes it a focal point for both multinational corporations and domestic producers seeking to establish or expand their footprint.

Strategic Positions of Leading Vaccine Manufacturers

Leading industry players are leveraging a variety of strategic initiatives to consolidate market share and drive innovation. One multinational manufacturer has prioritized capacity expansion in its Vero cell vaccine lines to address forecasted demand spikes, while another global company has positioned its purified chick embryo cell portfolio as a cost-competitive alternative in price-sensitive markets. Strategic alliances between vaccine developers and contract manufacturing organizations are also accelerating pipeline throughput, enabling rapid scale-up of novel formulations such as thermostable, lyophilized presentations.

In parallel, several companies are strengthening their digital offerings by integrating patient adherence platforms and cold-chain monitoring solutions with existing distribution networks. This not only enhances product differentiation but also delivers real-time analytics that inform supply planning and post-market surveillance. Some players have pursued mergers and acquisitions to broaden their geographic reach, targeting domestic firms in high-growth Asia-Pacific markets to gain regulatory expertise and local market insights. Meanwhile, targeted licensing agreements have emerged as an effective means for established developers to penetrate new territories without direct capital investment.

Ultimately, the competitive landscape is defined by the ability to harmonize technical excellence with agile commercial execution. Companies that excel in aligning manufacturing scalability, regulatory compliance, and customer-centric distribution will secure a sustainable advantage in the evolving rabies vaccine sector.

Actionable Strategies for Competitive Advantage

To thrive in the human rabies vaccine market, industry leaders should adopt a multi-pronged approach that balances innovation with operational resilience. First, expanding intradermal training programs among healthcare providers can unlock significant cost efficiencies and extend vaccine reach, particularly in resource-constrained regions. Concurrently, diversifying supply chains by engaging multiple contract manufacturing partners mitigates the risk of tariff‐induced price shocks and strengthens procurement agility.

Next, stakeholders should prioritize the development and deployment of thermostable, lyophilized formulations to address cold-chain constraints and expand delivery options in remote or tropical environments. Integrating digital adherence tools into vaccine packaging and distribution channels not only bolsters patient compliance but also yields actionable data to refine forecasting and inventory management. Partnerships with hospital pharmacies, online outlets, and retail chains can further enhance market penetration by aligning with consumer behaviors and institutional purchasing patterns.

Finally, active engagement with regulatory agencies and participation in One Health collaborations will accelerate market access and foster cross‐sector alignment. By harmonizing development strategies with emerging global standards and local public health objectives, companies can ensure smoother approvals and more impactful vaccination campaigns.

Robust Framework Underpinning Research Insights

This analysis rests upon a rigorous, multi-phase methodology designed to deliver actionable insights with robust validation. Primary research included in-depth interviews with key opinion leaders-ranging from immunologists and epidemiologists to procurement executives in both public and private sectors-to capture firsthand perspectives on emerging trends and strategic priorities. Secondary research drew upon regulatory filings, patent databases, and government health agency reports, as well as peer-reviewed literature to enrich our understanding of technological advancements and policy developments.

Quantitative data were compiled from global trade databases, hospital procurement records, and distribution channel analytics to map current market shares and volume flows. Qualitative insights were integrated through thematic coding of expert interviews and field observations, enabling us to identify latent opportunities and potential bottlenecks. Triangulation across multiple data sources ensured the reliability of our findings, while periodic peer reviews by external domain specialists enhanced objectivity.

Finally, all conclusions were stress-tested against scenario analyses that consider variables such as tariff adjustments, regulatory shifts, and outbreak contingencies. This comprehensive framework underpins the strategic recommendations and segmentation insights presented herein.

Synergizing Insights to Foster Impactful Decision Making

The confluence of novel vaccine technologies, evolving regulatory frameworks, and shifting trade landscapes presents both challenges and opportunities for the human rabies prophylaxis market. Stakeholders must navigate tariff headwinds while capitalizing on dose-sparing intradermal protocols and thermostable formulations to reach underserved populations. Segmentation analysis underscores the necessity of tailored strategies for vaccine type, class, administration route, formulation, end users, and distribution channels, all of which vary significantly across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Leading manufacturers that harmonize advanced cell culture methods, strategic supply chain diversification, and digital adherence solutions will be well-positioned to capture emerging growth pockets. At the same time, engagement with One Health initiatives and proactive regulatory alignment will accelerate market access and reinforce public health outcomes. By integrating the insights and recommendations contained in this summary, decision-makers can craft resilient, forward-looking strategies that not only withstand geopolitical and economic fluctuations but also drive meaningful progress toward eliminating human rabies deaths globally.

In closing, the imperative is clear: only through agile execution, strategic collaboration, and unwavering commitment to innovation can the global community realize the ambitious goal of a world free from rabies.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Vaccine Type
    • Post Exposure Prophylaxis
    • Pre Exposure Prophylaxis
  • Vaccine Class
    • Human Diploid Cell
    • Purified Chick Embryo Cell
    • Purified Vero Cell
  • Route Of Administration
    • Intradermal
    • Intramuscular
  • Formulation
    • Liquid
    • Lyophilized
  • End User
    • Clinics
    • Hospitals
    • Research Institutes
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Sanofi SA
  • GlaxoSmithKline plc
  • Bharat Biotech International Limited
  • Indian Immunologicals Limited
  • Valneva SE
  • China National Pharmaceutical Group Co., Ltd.
  • PT Bio Farma (Persero) Tbk
  • Hualan Biological Engineering Inc.
  • Changchun Institute of Biological Products Co., Ltd.
  • Chengdu Institute of Biological Products Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human Rabies Vaccines Market, by Vaccine Type
8.1. Introduction
8.2. Post Exposure Prophylaxis
8.3. Pre Exposure Prophylaxis
9. Human Rabies Vaccines Market, by Vaccine Class
9.1. Introduction
9.2. Human Diploid Cell
9.3. Purified Chick Embryo Cell
9.4. Purified Vero Cell
10. Human Rabies Vaccines Market, by Route of Administration
10.1. Introduction
10.2. Intradermal
10.3. Intramuscular
11. Human Rabies Vaccines Market, by Formulation
11.1. Introduction
11.2. Liquid
11.3. Lyophilized
12. Human Rabies Vaccines Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.4. Research Institutes
13. Human Rabies Vaccines Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Americas Human Rabies Vaccines Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Human Rabies Vaccines Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Human Rabies Vaccines Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Sanofi SA
17.3.2. GlaxoSmithKline plc
17.3.3. Bharat Biotech International Limited
17.3.4. Indian Immunologicals Limited
17.3.5. Valneva SE
17.3.6. China National Pharmaceutical Group Co., Ltd.
17.3.7. PT Bio Farma (Persero) Tbk
17.3.8. Hualan Biological Engineering Inc.
17.3.9. Changchun Institute of Biological Products Co., Ltd.
17.3.10. Chengdu Institute of Biological Products Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. HUMAN RABIES VACCINES MARKET MULTI-CURRENCY
FIGURE 2. HUMAN RABIES VACCINES MARKET MULTI-LANGUAGE
FIGURE 3. HUMAN RABIES VACCINES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. HUMAN RABIES VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. HUMAN RABIES VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HUMAN RABIES VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HUMAN DIPLOID CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED CHICK EMBRYO CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED VERO CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 42. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 43. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 48. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 49. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 51. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 73. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 74. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 79. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 80. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 82. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 85. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 86. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 88. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 91. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 92. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 94. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 97. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 98. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 100. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 103. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 104. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 106. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 109. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 110. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 112. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 115. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 116. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 121. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 127. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 128. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 130. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 139. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 140. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 142. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 145. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 146. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 148. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 151. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 152. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 154. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 157. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 158. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 160. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 163. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 164. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 166. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 169. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 170. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 172. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 175. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 176. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 178. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 181. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 182. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 184. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 187. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 188. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 190. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 193. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 194. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 205. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 206. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 207. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 209. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 212. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 213. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 215. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 218. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 219. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 221. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 230. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 231. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 233. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 242. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 243. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 245. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 266. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 267. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 269. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 272. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 275. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. HUMAN RABIES VACCINES MARKET SHARE, BY KEY PLAYER, 2024
TABLE 278. HUMAN RABIES VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Human Rabies Vaccines market report include:
  • Sanofi SA
  • GlaxoSmithKline plc
  • Bharat Biotech International Limited
  • Indian Immunologicals Limited
  • Valneva SE
  • China National Pharmaceutical Group Co., Ltd.
  • PT Bio Farma (Persero) Tbk
  • Hualan Biological Engineering Inc.
  • Changchun Institute of Biological Products Co., Ltd.
  • Chengdu Institute of Biological Products Co., Ltd.

Methodology

Loading
LOADING...

Table Information